Trial Profile
Rheumatoid Arthritis with Orencia Trial Toward Sjogren's syndrome Endocrinopathy (ROSE II Trial)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis; Sjogren's syndrome
- Focus Therapeutic Use
- Acronyms ROSE II
- 27 Jul 2022 Status changed from active, no longer recruiting to completed.
- 23 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.